CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Stock Information for Profound Medical Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Profound Medical Corp.

Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th - Conference Call to Follow
Profound Medical Honored with INOVAIT's 2025-2026 Mount Logan Award Recognizing the TULSA Procedure(TM) for Prostate Disease
PRO FAMILIA and Profound Medical Celebrate 500 Sonalleve® Procedures, Expanding Access to Incision-Free Care for Women's Health
Profound Medical Announces Upcoming Investor Events
Mount Sinai Becomes First in Metro New York to Deliver Incision-Free, MRI-Guided Prostate Treatment with TULSA-PRO®
Profound Surpasses 2025 TULSA-PRO® Installed Base Goal

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.